Sod1 Mutation Associated Als Therapeutics
1. Qalsody patent expiration
Treatment: Treatment of amyotrophic lateral sclerosis (als) in adults who have a mutation in the superoxide dismutase 1 (sod1) gene
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US10385341 | BIOGEN MA | Compositions for modulating SOD-1 expression |
Apr, 2035
(9 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10968453 | BIOGEN MA | Compositions for modulating SOD-1 expression |
Apr, 2035
(9 years from now) | |
| US10669546 | BIOGEN MA | Compositions for modulating SOD-1 expression |
Apr, 2035
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Apr 25, 2028 |
| Orphan Drug Exclusivity(ODE-432) | Apr 25, 2030 |
Drugs and Companies using TOFERSEN ingredient
NCE-1 date: 26 April, 2027
Market Authorisation Date: 25 April, 2023
Dosage: SOLUTION
More Information on Dosage
QALSODY family patents
